Lilly Sees More Dealmaking as GLP-1 Wins Expand Market
Eli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Timing bond allocations can reduce risk and stabilize income in retirement. Learn indicators and phased approaches to use bonds effectively.
22,161 articlesEli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
OpenAI confronts multi-front pressure as its largest backer rethinks bets, Microsoft shifts workloads inward, and riv...
Anthropic unveils a $150 million fellowship to place 1,000 AI coaches with nonprofits for a year, funded as the compa...
Hyperliquid's HYPE leapt about 10% in 24 hours, approaching $72 as ETF-backed products pour in funds and SpaceX perpe...
Billionaire investor Mark Cuban warns popular bets could quietly erode wealth as funding costs rise and consumer conf...
Investors chasing a SpaceX IPO windfall risk turning luck into poor strategy. Experts warn the real lesson is risk ma...
The bitcoin treasury strategy that propelled MicroStrategy into crypto prominence is under stress as bitcoin prices r...
Investors cheered a strong tesla quarterly deliveries jump, yet the stock traded lower. This article unpacks the reas...
London-based Fleek lands $25 million in a Series B to grow its network of vintage wholesalers and U.S./EU retailers. ...
A biotech stock can surge on hype, but smart investors dig into the data behind the rally. This guide breaks down how...
Investing in nuclear energy can feel like riding a high-speed train. Oklo’s small modular reactors promise a greener ...
When a CEO sells stock, investors listen. This article breaks down what the Electronic Arts CEO's roughly $1 million ...